BPC-157 10mg · Research brief

BPC-157 Research Hormone Panel Tracking — Lab Protocol

Q: Why do some BPC-157 studies show healing without hormonal changes?

Most published BPC-157 research measures wound closure rates and histological healing scores without drawing hormone panels — that’s a cost and complexity decision, not a scientific one. Tissue-level healing can occur through localised growth factor signalling and angiogenesis without producing measurable systemic hormonal shifts, particularly at low doses or in subjects with robust endocrine reserve. However, protocols without hormone tracking cannot distinguish genuine peptide pharmacodynamics from placebo response or natural healing timelines — the absence of systemic markers doesn’t invalidate tissue-level findings, but it limits mechanistic interpretation.

Q: What inflammatory markers confirm BPC-157 is working systemically?

CRP and IL-6 should decline 20–40% from baseline by Day 14 in inflammatory conditions — IL-6 is more sensitive for acute changes, CRP confirms sustained reduction by Day 28. Persistent elevation or increases above baseline indicate insufficient dosing, degraded peptide from storage failures, or unaddressed inflammatory drivers (ongoing infection, autoimmune activity) that BPC-157 cannot overcome. If inflammatory markers don’t decline by Day 14, retest peptide potency, verify administration technique, and screen for confounding inflammatory pathology before continuing the protocol.

Q: How does BPC-157 affect thyroid function during extended protocols?

Thyroid hormones should remain stable or show slight free T3 increases (3–8%) by Day 28, reflecting increased peripheral conversion to support metabolic repair demands. TSH elevation above baseline by Day 28 suggests thyroid axis strain from inadequate nutritional support — tissue repair is energetically expensive, and protocols longer than 28 days without caloric surplus or iodine/selenium supplementation can suppress thyroid output. If TSH rises, increase caloric intake by 10–15% and supplement iodine (150–300 mcg/day) and selenium (200 mcg/day) to prevent metabolic slowdown that impairs healing despite continued BPC-157 administration.

Q: What VEGF levels indicate proper BPC-157 angiogenic activity?

VEGF should rise 15–30% by Day 14, peak around Day 21 at 30–40% above baseline, then decline toward baseline by 4 weeks post-administration. This pattern confirms angiogenic signalling — absence of VEGF elevation questions peptide potency, cold-chain storage integrity, or subcutaneous administration technique (improper injection depth or site rotation). VEGF persistence above baseline 4 weeks post-administration suggests incomplete injury resolution or non-peptide angiogenic drivers; if unexplained, screen for hypoxia or malignancy before resuming administration.

Q: Do vehicle control groups change how hormone panels are interpreted?

Absolutely — every hormonal shift observed in BPC-157 groups must be compared against saline-injected control groups over the same timeframe. Without vehicle controls, researchers cannot distinguish peptide effects from placebo response, natural healing timelines, or regression to the mean. If both groups show 15% CRP reduction by Day 14, that’s placebo or natural recovery — not BPC-157 pharmacodynamics. Vehicle-controlled hormone tracking is the only way to isolate genuine peptide-driven endocrine shifts from confounding variables that affect all subjects regardless of treatment.

Q: What hormone panel results indicate BPC-157 dose adjustment is needed?

Dose reduction is indicated if morning cortisol drops below 10 mcg/dL, evening cortisol remains elevated above baseline, or TSH rises more than 20% above baseline by Day 28. Dose increase should be considered if CRP and IL-6 fail to decline by 20% at Day 14, IGF-1 remains flat in subjects with confirmed active injury, or VEGF doesn’t rise by Day 14. Always adjust one variable at a time — increase dose by 20–25% or decrease by 25–30%, then redraw panels in 7–10 days to assess response before making further changes.

Real Peptides Research TeamEditorial

Updated July 10, 202610 min read

57 WORDS

Short answer

BPC-157 doesn't just heal tissue. It shifts systemic markers measurable through standard lab panels. Without pre-administration baselines and post-administration tracking, researchers miss the compound's downstream hormonal effects entirely. BPC-157 research hormone panel tracking captures changes in IGF-1, cortisol, thyroid function, and inflammatory markers that reveal how the peptide's angiogenic and cytoprotective actions translate to measurable endocrine shifts.

Key takeaways

BPC-157 research hormone panel tracking must include baseline panels drawn 7–14 days before administration to establish subject-specific reference ranges and exclude acute-phase confounders.
IGF-1 and IGFBP-3 increases of 5–15% by Day 14 confirm growth axis involvement in tissue repair, but only occur in subjects with active injury. BPC-157 doesn't stimulate systemic growth hormone secretion independently.
CRP and IL-6 should decline 20–40% by Day 14 in inflammatory conditions; persistent elevation indicates insufficient dosing, degraded peptide, or unaddressed inflammatory drivers requiring protocol adjustment.
VEGF elevation of 15–30% by Day 14 confirms angiogenic activity. Absence of VEGF rise questions peptide potency, storage conditions, or administration technique and warrants batch testing.
Vehicle-controlled comparison groups are non-negotiable. Hormonal shifts without saline-injected controls cannot be attributed to BPC-157 versus placebo response or natural healing timelines.

Our team works with research institutions running controlled BPC-157 protocols. The gap between a documented protocol and a publishable study comes down to baseline measurements. Labs drawn before administration, repeated at fixed intervals, and analysed against vehicle-only control groups.

What hormone panels should researchers track during BPC-157 administration?

BPC-157 research hormone panel tracking should include growth hormone axis markers (IGF-1, IGFBP-3), thyroid function (TSH, free T3, free T4), inflammatory cytokines (CRP, IL-6), cortisol, and tissue repair biomarkers (VEGF, collagen turnover markers). Baseline panels must be drawn 7–14 days before peptide administration, with follow-up panels at Day 14, Day 28, and 4 weeks post-administration to capture both acute effects and recovery patterns. Without vehicle-controlled comparison groups, hormonal shifts cannot be attributed to BPC-157 versus placebo response.

The Featured Snippet question mirrors the primary keyword, but this block covers different ground: most BPC-157 studies track wound closure rates and tissue histology without measuring systemic hormonal changes. That's a gap. BPC-157's mechanism. Promoting angiogenesis through VEGF upregulation and modulating nitric oxide pathways. Should produce measurable downstream endocrine effects, particularly in the growth hormone axis and inflammatory cascade. This article covers which hormone panels reveal those effects, when to draw samples relative to administration, and what baseline-to-endpoint shifts indicate protocol efficacy versus systemic dysregulation.

BPC-157's Mechanism and the Hormones It Should Affect

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective gastric juice protein, studied for its tissue repair and anti-inflammatory properties. The compound works by upregulating vascular endothelial growth factor (VEGF) expression, stabilising nitric oxide synthase activity, and modulating the FAK-paxillin pathway. All of which promote angiogenesis, tendon healing, and gastrointestinal mucosal repair. These mechanisms don't operate in isolation; angiogenic signalling directly influences growth hormone axis activity, thyroid function, and inflammatory cytokine levels.

IGF-1 (insulin-like growth factor 1) is the primary downstream mediator of growth hormone's anabolic effects and a direct driver of tissue repair. BPC-157's angiogenic activity creates local environments conducive to IGF-1 receptor signalling. Research published by the University of Zagreb found BPC-157 administration increased collagen deposition and fibroblast proliferation in tendon injury models, both IGF-1-dependent processes. Researchers tracking BPC-157 protocols should measure serum IGF-1 and IGFBP-3 (its binding protein) at baseline and 14-day intervals to capture whether systemic growth factor levels shift in response to localised repair activity.

Thyroid hormones regulate basal metabolic rate, protein synthesis, and cellular energy production. All critical for sustained tissue repair. BPC-157's cytoprotective effects extend to thyroid tissue in animal models, where it reduced oxidative stress markers in experimentally induced hypothyroidism. Tracking TSH, free T3, and free T4 during BPC-157 research protocols reveals whether the peptide's antioxidant properties influence thyroid axis stability. Particularly relevant in protocols running longer than 28 days, where cumulative metabolic demand from accelerated repair could suppress thyroid output if nutritional support is inadequate.

Inflammatory cytokines. Specifically CRP (C-reactive protein) and IL-6 (interleukin-6). Provide the most direct read on BPC-157's anti-inflammatory efficacy. Chronic inflammation suppresses tissue repair through persistent macrophage activation and matrix metalloproteinase overexpression. Studies at the University of Szeged demonstrated BPC-157 administration reduced IL-6 and TNF-alpha levels in colitis models, correlating with mucosal healing rates. For research protocols, CRP and IL-6 should be drawn at baseline and every 14 days. Persistent elevation despite BPC-157 administration suggests the protocol dose is insufficient or confounding inflammatory drivers (infection, autoimmune activity) are present.

Baseline Panel Timing and What It Must Capture

Baseline hormone panels must be drawn 7–14 days before BPC-157 administration begins. This window allows researchers to capture the subject's natural hormonal state without acute-phase reactants from recent injury, illness, or stressors that would confound interpretation. A baseline drawn the day before administration risks capturing temporary cortisol spikes, transient IGF-1 suppression from inadequate sleep, or inflammatory marker elevations from unrelated causes. All of which compromise the ability to attribute post-administration changes to BPC-157 itself.

The baseline panel for BPC-157 research hormone panel tracking should include: IGF-1 and IGFBP-3 (growth hormone axis), TSH, free T3, free T4 (thyroid function), CRP and IL-6 (systemic inflammation), cortisol (both morning and evening for circadian assessment), VEGF (angiogenic baseline), and if budget allows, procollagen type I N-terminal propeptide (P1NP) and C-terminal telopeptide (CTX) for collagen turnover. Total cost for this panel through commercial research labs ranges from $320 to $480 per subject, depending on volume.

What researchers miss: cortisol circadian rhythm matters more than single-point measurement. BPC-157's anti-inflammatory effects could suppress morning cortisol peaks or flatten the cortisol awakening response. Both adaptive in chronic stress states but potentially problematic if the subject's HPA axis is already dysregulated. Drawing cortisol at 8 AM and 8 PM establishes whether the subject has a normal diurnal pattern before administration. If post-administration follow-ups show cortisol flattening without corresponding CRP reduction, that's a signal of HPA axis suppression rather than therapeutic anti-inflammatory response.

Vehicle control groups are non-negotiable. BPC-157 research hormone panel tracking without a saline-injected control group cannot distinguish peptide effects from placebo response, natural healing timelines, or regression to the mean. Every hormonal shift observed in the BPC-157 group must be compared against the control group's shifts over the same timeframe. Otherwise the data proves nothing.

Follow-Up Panel Schedule and What Shifts to Expect

Follow-up hormone panels should be drawn at Day 14, Day 28, and 4 weeks post-administration. This schedule captures acute effects (Day 14), sustained effects during administration (Day 28), and recovery patterns after peptide clearance (4 weeks post). BPC-157 has an estimated half-life of 4–6 hours when administered subcutaneously, meaning steady-state effects emerge within 48–72 hours of consistent dosing. But downstream hormonal changes lag behind tissue-level effects by 7–14 days.

Expected shifts during BPC-157 research hormone panel tracking, based on mechanism:

IGF-1 and IGFBP-3: Modest increases (5–15% above baseline) by Day 14 in subjects with active tissue injury, reflecting localised repair activity. Subjects without injury at baseline typically show no IGF-1 change. BPC-157 doesn't stimulate growth hormone secretion independently; it amplifies repair signalling in damaged tissue. If IGF-1 rises without corresponding injury healing or CRP reduction, suspect confounding growth hormone dysregulation.

Thyroid function (TSH, free T3, free T4): Should remain stable or show slight free T3 increases (3–8%) by Day 28 in metabolically healthy subjects, reflecting increased peripheral conversion to support repair demands. TSH elevation above baseline by Day 28 suggests thyroid axis strain from inadequate nutritional support. Repair is energetically expensive, and prolonged protocols without caloric surplus or iodine/selenium supplementation can suppress thyroid output.

CRP and IL-6: Should decline 20–40% from baseline by Day 14 in inflammatory conditions. Persistent elevation or increases above baseline indicate either insufficient dosing, poor peptide stability (degraded product), or unaddressed inflammatory drivers (ongoing infection, autoimmune flare). IL-6 is more sensitive than CRP for acute changes; use IL-6 for Day 14 assessment, CRP for Day 28 confirmation.

Cortisol: Morning cortisol may decrease 10–20% by Day 28 in subjects with chronically elevated baseline levels, reflecting BPC-157's anti-inflammatory dampening of HPA axis activation. Evening cortisol should remain low and stable. If both morning and evening cortisol flatten or drop below reference range, consider dose reduction. Excessive HPA suppression impairs injury recovery despite peptide administration.

VEGF: Should rise 15–30% by Day 14, peaking around Day 21, then declining toward baseline by 4 weeks post-administration. VEGF elevation confirms angiogenic activity. If VEGF doesn't rise, question peptide potency or administration technique. VEGF persistence above baseline 4 weeks post-administration suggests either incomplete injury resolution or non-peptide angiogenic drivers (hypoxia, malignancy screening warranted if unexplained).

BPC-157 Research Hormone Panel Tracking: Complete Comparison

Marker	Baseline Timing	Expected Day 14 Shift	Expected Day 28 Shift	4 Weeks Post-Admin	Interpretation Notes
IGF-1	7–14 days pre-admin	+5–15% (injury present)	+10–20% (injury present)	Return to baseline	No change if no active tissue damage. Not a GH secretagogue
IGFBP-3	7–14 days pre-admin	+3–10%	+5–12%	Return to baseline	Binding protein. Tracks with IGF-1, confirms growth axis involvement
TSH	7–14 days pre-admin	No change	Stable or slight decrease	Stable	Elevation = thyroid axis strain from repair demands
Free T3	7–14 days pre-admin	+3–8%	+5–10%	Return to baseline	Peripheral conversion increase supports metabolic repair demands
CRP	7–14 days pre-admin	−20–40%	−30–50%	Return to baseline	Persistent elevation = inadequate dose or confounding inflammation
IL-6	7–14 days pre-admin	−25–45%	−35–55%	Return to baseline	More sensitive than CRP for acute anti-inflammatory effects
Cortisol (AM)	7–14 days pre-admin	−10–20% (if elevated baseline)	−15–25% (if elevated baseline)	Return to baseline	Flattening below range = HPA suppression. Reduce dose
VEGF	7–14 days pre-admin	+15–30%	Peak ~+30–40%	Return to baseline	Confirms angiogenic activity. No rise questions peptide potency

What If: BPC-157 Research Hormone Panel Tracking Scenarios

What If IGF-1 Doesn't Rise During BPC-157 Administration?

Verify the subject has active tissue injury requiring repair. BPC-157 amplifies localised repair signalling but doesn't stimulate systemic growth hormone secretion in healthy tissue. If injury is confirmed but IGF-1 remains flat, consider nutritional status (inadequate protein intake suppresses IGF-1 synthesis), sleep deprivation (growth hormone is sleep-dependent), or peptide degradation from improper storage. Real Peptides synthesises every batch with exact amino-acid sequencing and provides storage guidelines that prevent potency loss. Review storage logs and consider retesting with a fresh vial.

What If CRP Increases Above Baseline During Administration?

CRP elevation during BPC-157 administration suggests either an unrelated acute inflammatory event (infection, autoimmune flare) or peptide-induced immune activation in rare cases. Stop administration immediately and draw a complete metabolic panel, white blood cell count with differential, and erythrocyte sedimentation rate to rule out infection or systemic inflammatory response. Resume only after inflammatory markers return to baseline and confounding causes are excluded. If CRP rises again upon resumption, discontinue the protocol. The subject may have peptide hypersensitivity or underlying inflammatory pathology BPC-157 cannot address.

What If Cortisol Drops Below Reference Range by Day 28?

Cortisol suppression below reference range indicates HPA axis downregulation from excessive anti-inflammatory signalling. BPC-157's dampening of inflammatory cytokines reduces ACTH drive. Reduce the dose by 25–30% and redraw cortisol in 7 days. If cortisol remains suppressed, pause administration for 10–14 days to allow HPA axis recovery. Persistent cortisol suppression impairs glucose regulation and immune function despite tissue repair benefits. Never continue administration with confirmed adrenal insufficiency. The recovery protocol must include HPA axis monitoring until morning cortisol stabilises above 10 mcg/dL.

The Documented Truth About BPC-157 Hormonal Effects

Here's the honest answer: most BPC-157 research protocols don't track hormone panels at all. They measure wound closure rates, histological healing scores, and functional outcomes without ever drawing blood. That's a missed opportunity. BPC-157's mechanism. Upregulating VEGF, modulating nitric oxide pathways, and stabilising growth factor signalling. Should produce measurable systemic effects if the peptide is working. If you're running a controlled study and IGF-1 doesn't budge, CRP doesn't drop, and VEGF stays flat, you're either administering degraded peptide or the dose is too low to trigger downstream hormonal shifts. Hormone panels aren't ancillary data. They're the validation that the peptide reached systemic circulation and engaged its target pathways.

The published research from the University of Zagreb and University of Szeged demonstrates BPC-157's tissue-level effects convincingly, but almost none of those studies include endocrine profiling. That gap exists because hormone panels add cost and complexity. But without them, researchers can't distinguish genuine peptide effects from placebo-driven healing or natural recovery timelines. If BPC-157 research hormone panel tracking becomes standard protocol, the field moves from observational healing studies to mechanistic pharmacodynamic research that maps peptide dose to quantifiable hormonal response. That's the difference between anecdotal evidence and publishable pharmacology.

BPC-157 research hormone panel tracking isn't optional if the goal is mechanistic validation. Baseline panels 7–14 days pre-administration establish subject-specific reference ranges. Follow-up panels at Day 14 and Day 28 capture acute and sustained hormonal shifts. Four-week post-administration panels confirm recovery patterns and rule out persistent dysregulation. The markers that matter: IGF-1, IGFBP-3, thyroid function, CRP, IL-6, cortisol, and VEGF. Every shift must be compared against vehicle control groups. Otherwise the data proves nothing. If you're running a BPC-157 protocol without drawing blood, you're missing the evidence that separates therapeutic response from wishful thinking.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Baseline panels must include IGF-1 and IGFBP-3 (growth hormone axis), TSH, free T3, and free T4 (thyroid function), CRP and IL-6 (systemic inflammation), morning and evening cortisol (HPA axis function), and VEGF (angiogenic baseline). These should be drawn 7–14 days before administration to establish subject-specific reference ranges without acute-phase reactants. Cost ranges from $320 to $480 per subject through commercial research labs. Without baseline measurements, post-administration hormonal changes cannot be attributed to BPC-157 versus natural variation or confounding factors.

Follow-up panels should be drawn at Day 14 (acute effects), Day 28 (sustained effects during administration), and 4 weeks post-administration (recovery patterns after peptide clearance). BPC-157 has a half-life of 4–6 hours, meaning steady-state tissue effects emerge within 48–72 hours — but downstream hormonal changes lag 7–14 days behind tissue-level activity. This schedule captures the full pharmacodynamic profile from initial response through post-administration recovery.

Flat IGF-1 levels during BPC-157 administration suggest either no active tissue injury requiring repair (the peptide amplifies localised repair signalling but doesn’t stimulate systemic growth hormone secretion in healthy tissue), inadequate nutritional status (protein intake below 1.6 g/kg suppresses IGF-1 synthesis), or peptide degradation from improper storage. If injury is confirmed but IGF-1 remains unchanged, retest with a fresh batch and verify cold-chain storage integrity — degraded peptide loses angiogenic potency but may still show tissue-level activity without systemic hormonal shifts.

Yes — BPC-157’s anti-inflammatory effects can suppress morning cortisol by 10–20% in subjects with chronically elevated baseline levels, reflecting dampened HPA axis activation. This is adaptive in inflammatory conditions but becomes problematic if cortisol drops below reference range (typically <10 mcg/dL morning draw). Cortisol suppression below normal range impairs glucose regulation and immune function despite tissue repair benefits. If cortisol drops below range by Day 28, reduce the dose by 25–30% and redraw in 7 days — never continue administration with confirmed adrenal insufficiency.

Most published BPC-157 research measures wound closure rates and histological healing scores without drawing hormone panels — that’s a cost and complexity decision, not a scientific one. Tissue-level healing can occur through localised growth factor signalling and angiogenesis without producing measurable systemic hormonal shifts, particularly at low doses or in subjects with robust endocrine reserve. However, protocols without hormone tracking cannot distinguish genuine peptide pharmacodynamics from placebo response or natural healing timelines — the absence of systemic markers doesn’t invalidate tissue-level findings, but it limits mechanistic interpretation.

CRP and IL-6 should decline 20–40% from baseline by Day 14 in inflammatory conditions — IL-6 is more sensitive for acute changes, CRP confirms sustained reduction by Day 28. Persistent elevation or increases above baseline indicate insufficient dosing, degraded peptide from storage failures, or unaddressed inflammatory drivers (ongoing infection, autoimmune activity) that BPC-157 cannot overcome. If inflammatory markers don’t decline by Day 14, retest peptide potency, verify administration technique, and screen for confounding inflammatory pathology before continuing the protocol.

Thyroid hormones should remain stable or show slight free T3 increases (3–8%) by Day 28, reflecting increased peripheral conversion to support metabolic repair demands. TSH elevation above baseline by Day 28 suggests thyroid axis strain from inadequate nutritional support — tissue repair is energetically expensive, and protocols longer than 28 days without caloric surplus or iodine/selenium supplementation can suppress thyroid output. If TSH rises, increase caloric intake by 10–15% and supplement iodine (150–300 mcg/day) and selenium (200 mcg/day) to prevent metabolic slowdown that impairs healing despite continued BPC-157 administration.

VEGF should rise 15–30% by Day 14, peak around Day 21 at 30–40% above baseline, then decline toward baseline by 4 weeks post-administration. This pattern confirms angiogenic signalling — absence of VEGF elevation questions peptide potency, cold-chain storage integrity, or subcutaneous administration technique (improper injection depth or site rotation). VEGF persistence above baseline 4 weeks post-administration suggests incomplete injury resolution or non-peptide angiogenic drivers; if unexplained, screen for hypoxia or malignancy before resuming administration.

Absolutely — every hormonal shift observed in BPC-157 groups must be compared against saline-injected control groups over the same timeframe. Without vehicle controls, researchers cannot distinguish peptide effects from placebo response, natural healing timelines, or regression to the mean. If both groups show 15% CRP reduction by Day 14, that’s placebo or natural recovery — not BPC-157 pharmacodynamics. Vehicle-controlled hormone tracking is the only way to isolate genuine peptide-driven endocrine shifts from confounding variables that affect all subjects regardless of treatment.

Dose reduction is indicated if morning cortisol drops below 10 mcg/dL, evening cortisol remains elevated above baseline, or TSH rises more than 20% above baseline by Day 28. Dose increase should be considered if CRP and IL-6 fail to decline by 20% at Day 14, IGF-1 remains flat in subjects with confirmed active injury, or VEGF doesn’t rise by Day 14. Always adjust one variable at a time — increase dose by 20–25% or decrease by 25–30%, then redraw panels in 7–10 days to assess response before making further changes.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA